-- Earnings Flash (RDUS) RADIUS HEALTH Posts Q1 Revenue $43.2M, vs. Street Est of $51.3M
7:31AM ET 5/05/2022 MT Newswires...
Quotes Snapshot > RDUS
Radius Health Inc RDUS:NASDAQ
Last Price$5.84NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22
Today's Change-0.05(0.85%)
Bid (Size)$5.50 (1)
Ask (Size)$6.12 (2)
Day Low / High$4.97 - 5.86
Volume2.1 M
Read more news Recent News
-- Earnings Flash (RDUS) RADIUS HEALTH Reports Q1 Loss $-0.19, vs. Street Est of $-0.18
7:31AM ET 5/05/2022 MT Newswires...
Radius Health Names New CFO
9:59AM ET 3/16/2022 MT NewswiresRadius Health (RDUS) said Wednesday that Mark Conley was named as its new chief financial officer Conley most recently served as vice president of finance...
Radius Files Supplemental New Drug Application With FDA for Tymlos Injection for Men With Osteoporosis
10:28AM ET 3/01/2022 MT NewswiresRadius Health (RDUS) said Tuesday it has filed a supplemental new drug application with the US Food and Drug Administration for its Tymlos injection to...
View all Commentary and Analysis
Radius Health, Inc. 2022 Q1 - Results - Earnings Call Presentation
11:30PM ET 5/12/2022 Seeking AlphaRadius Health, Inc. (RDUS) CEO Kelly Martin On Q1 2022 Results - Earnings Call Transcript
2:36PM ET 5/06/2022 Seeking AlphaRadius Health, Inc.'s (RDUS) CEO Kelly Martin on Q4 2021 Results - Earnings Call Transcript
3:32PM ET 2/24/2022 Seeking AlphaReevaluating Radius Health
3:20PM ET 2/24/2022 Seeking AlphaCompany Profile
Business DescriptionRadius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. View company web site for more details
| Address | 22 Boston Wharf Road Boston, Massachusetts 02210 |
| Phone | +1.617.551.4000 |
| Number of Employees | 398 |
| Recent SEC Filing | 05/05/2022 8-K |
| President, Chief Executive Officer & Director | George Kelly Martin |
| CFO, Treasurer, Chief Accounting Officer & VP | Mark Conley |
| Chief Medical Officer | Bruce Mitlak |
| Head-Information Technology | Allison Ross |
Company Highlights
| Price Open | $5.61 |
| Previous Close | $5.84 |
| 52 Week Range | $4.97 - 23.00 |
| Market Capitalization | $277.8 M |
| Shares Outstanding | 47.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.54 |
| Beta vs. S&P 500 | N/A |
| Revenue | $99.2 M |
| Net Profit Margin | -33.52% |
| Return on Equity | 29.44% |
Analyst Ratings as of 01/06/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |